| Revenue growth | 26.2% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin at 32% (37% excluding injectable facility and Stellon expenses). |
| Demand visibility | Strong, driven by increased business from existing customers and new acquisitions. |
| Management confidence | High; confident in outperforming industry growth and increasing wallet share. |
Growth
Revenue rose 26% YoY to ₹257.5 Cr; EBITDA grew 34% to ₹82.4 Cr with margins expanding 190 bps.
Outlook
Targeting 2-3 product launches annually; focus on injectable facility ramp-up and leveraging new approvals from ANVISA, PPB, and NDA.
Risks
Formulation revenue declined 23% YoY; regulatory compliance remains critical across diverse global manufacturing inspections.
Last quarter's promises, checked
Delivered
- Guided historical growth ~18% → delivered 26.2% (= BEAT)
- Guided API revenue growth → delivered 42% (= BEAT)
- Guided export recovery → delivered 46% surge (= BEAT)
Partly delivered
- Guided EBITDA margin 39-40% (adj.) → delivered 37% (adj.) (= PARTIAL)
Missed
- Guided formulation business recovery → delivered -23% YoY (= MISS)
Investor Presentation filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,356.00
- Market cap
- ₹14,186 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 51.5×Sector 47.4×
- Promoter holding
- 44.08%+0.00% QoQ
- FII holding
- 7.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Bonus Issue
Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.
Concord Biotech Bonus Issue
Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.
- Value
- ₹10.46 Cr
Concord Biotech Board Meeting Date
Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.
Concord Biotech Business Update
Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.
Concord Biotech Earnings Call Transcript: Key Takeaways
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech Annual General Meeting
Concord Biotech Ltd held its 41st Annual General Meeting on July 31, 2026, via video conferencing. The company summarized the proceedings and acknowledged participant queries.